Hydrogenology
Source-linked study record

Molecular hydrogen and extracorporeal gas exchange: a match made in heaven? An in vitro pilot study

Mouzakis FL, Hima F, Kashefi A, Greven J, Rink L, van der Vorst EPC, Jankowski J, Mottaghy K, Spillner J. · Biomedicines. 2024;12(8):1883.

PreclinicalOther formsPublished 2024Source checked
Study record, not medical adviceThis record reports what the source states. It is not medical advice and does not establish that molecular hydrogen is effective, safe or appropriate for any person.
Quick summary

Study at a glance

Evidence type

Preclinical

Population or model

Heparinized blood donated by seven healthy adult men, tested outside the body in six simultaneous circuit/control conditions.

Intervention and dose

One lipopolysaccharide-challenged circuit received a roughly 6% H₂ gas mixture through a 0.3 m² gas exchanger for six hours, producing 100–120 ppb dissolved H₂ in blood. · Approximately 6% H₂ in the exchanger gas and 100–120 ppb dissolved H₂. Circuit blood flow was 40 mL/min, which is not the H₂ gas flow.

Duration

Six hours of uninterrupted 40 mL/min blood circulation and continuous gas supply.

Reported result

The H₂ circuit showed lower hemolysis and several inflammatory/oxidative biomarkers than the LPS gas-exchanger circuit, most clearly IL-6 and MDA. MCP-1 did not significantly differ overall, MPO patterns left little margin for an H₂ comparison, and H₂ interfered with one blood-gas analyzer's pO₂ reading.

Main limitation

Pilot ex-vivo system, only male donors, six conditions share each donor sample, substantial hemolysis, multiple biomarkers, no living subject and no clinical ECMO outcome. German institutional/foundation/DFG support was reported for one author; authors declared no conflicts.

Evidence and classification

What kind of evidence is this?

Evidence type

Preclinical

Reported design

Repeated ex-vivo human-blood miniature-ECMO circuit experiment

Research topic

Critical care and ischemia-reperfusion

Administration form

Other forms

Information not yet classified

Some editorial classification fields are still pending. The source-reported outcomes and result are shown below; Hydrogenology does not infer a positive or negative signal from prose automatically.

Reported in the source

Methods

Population or model

Heparinized blood donated by seven healthy adult men, tested outside the body in six simultaneous circuit/control conditions.

Sample

Seven donor experiments; on each occasion one donor's approximately 300 mL blood primed five miniature ECMO circuits and one stationary control.

Duration

Six hours of uninterrupted 40 mL/min blood circulation and continuous gas supply.

Intervention

One lipopolysaccharide-challenged circuit received a roughly 6% H₂ gas mixture through a 0.3 m² gas exchanger for six hours, producing 100–120 ppb dissolved H₂ in blood.

Hydrogen form

Molecular H₂ supplied as part of a gas-exchanger mixture — not Brown's gas; exact carrier-gas composition was not stated.

Dose or H₂ specification

Approximately 6% H₂ in the exchanger gas and 100–120 ppb dissolved H₂. Circuit blood flow was 40 mL/min, which is not the H₂ gas flow.

Comparator

Stationary blood, reference ECMO, lipopolysaccharide ECMO and otherwise matched gas-exchanger circuits without H₂.

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Blood gases, dissolved H₂, hemolysis and MCP-1, MPO, MDA, thioredoxin-1 and IL-6.

Reported result

The H₂ circuit showed lower hemolysis and several inflammatory/oxidative biomarkers than the LPS gas-exchanger circuit, most clearly IL-6 and MDA. MCP-1 did not significantly differ overall, MPO patterns left little margin for an H₂ comparison, and H₂ interfered with one blood-gas analyzer's pO₂ reading.

Extraction completeness

The complete free PMC article, circuit table, figures and methods were checked for donor/circuit structure, gas and dissolved concentrations, missing gas flows, positive and null/measurement findings, funding and conflicts.

A reported association, difference or mechanism is not automatically a clinical benefit.

Interpretation limits

Limitations and applicability

Main methodological cautions

Pilot ex-vivo system, only male donors, six conditions share each donor sample, substantial hemolysis, multiple biomarkers, no living subject and no clinical ECMO outcome. German institutional/foundation/DFG support was reported for one author; authors declared no conflicts.

Applies directly to

Miniature ECMO circuits containing healthy donor blood; it does not establish safety or efficacy in ECMO patients.

No single-study GRADE certainty rating is assigned. Read how records and evidence assessments are prepared.

Sources and status

Sources and record status

Identifiers

PMID: 39200347 · DOI: 10.3390/biomedicines12081883

Publisher access

Free full article in PubMed Central.

Extraction basis

Complete PMC article and PubMed metadata; full-text extraction checked 9 August 2026.

Last reviewed

10 August 2026

Help the next reader

Help people check the facts before they buy.

Hydrogenology keeps 665 source-checked records accessible without advertising or product promotion.

Support independent access
Help us correct the recordReport a discrepancy

Send the exact difference between this page and the linked source. The study reference is attached automatically.